AbbVie (ABBV) Long-Term Investments (2012 - 2026)

AbbVie (ABBV) has reported Long-Term Investments for 15 consecutive years, with $266.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Long-Term Investments fell 14.19% year-over-year to $266.0 million in Q2 2026; TTM through Jun 2026 was $266.0 million, a 14.19% decrease from a year earlier, with the FY2025 full-year figure at $268.0 million, down 3.94% from the prior year.
• Long-Term Investments was $266.0 million for Q2 2026 at AbbVie, down from $268.0 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $310.0 million in Q2 2025 and troughed at $235.0 million in Q3 2022.
• A 5-year average of $273.2 million and a median of $270.0 million in 2024 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments fell 14.75% in 2022 and climbed 26.14% in 2023, its largest moves.
• Over 5 years, Long-Term Investments stood at $241.0 million in 2022, then advanced by 26.14% to $304.0 million in 2023, then retreated by 8.22% to $279.0 million in 2024, then slipped by 3.94% to $268.0 million in 2025, then fell by 0.75% to $266.0 million in 2026.
• The last three Long-Term Investments figures came in at $266.0 million (Q2 2026), $268.0 million (Q1 2026), and $268.0 million (Q4 2025), per Business Quant data.